Dendritic cells （DCs） comprise two functionally distinct subsets： plasmacytoid DCs （pDCs） and myeloid DCs （mDCs）. pDCs are specialized in rapid and massive se- cretion of type I interferon （IFN-I） in response...Dendritic cells （DCs） comprise two functionally distinct subsets： plasmacytoid DCs （pDCs） and myeloid DCs （mDCs）. pDCs are specialized in rapid and massive se- cretion of type I interferon （IFN-I） in response to nucleic acids through Toll like receptor （TLR）-7 or TLR-9. In this report, we characterized a CD56^＋ DC population that express typical pDC markers including CD123 and BDCA2 but produce much less IFN-I comparing with pDCs. In addition, CD56^＋ DCs cluster together with mDCs but not pDCs by genome-wide transcriptional profiling. Accordingly, CD56^＋ DCs functionally resemble mDCs by producing IL-12 upon TLR4 stimulation and priming naive T cells without prior activation. These data suggest that the CD56^＋ DCs represent a novel mDC subset mixed with some pDC features. A CD4^＋CD56^＋ hematological malignancy was classified as blastic plasmacytoid dendritic cell neoplasm （BPDCN） due to its expression of characteristic molecules of pDCs.However, we demonstrated that BPDCN is closer to CD56^＋ DCs than pDCs by global gene-expression pro- filing. Thus, we propose that the CD4^＋CD56^＋ neoplasm may be a tumor counterpart of CD56^＋ mDCs but not pDCs.展开更多
文摘Dendritic cells （DCs） comprise two functionally distinct subsets： plasmacytoid DCs （pDCs） and myeloid DCs （mDCs）. pDCs are specialized in rapid and massive se- cretion of type I interferon （IFN-I） in response to nucleic acids through Toll like receptor （TLR）-7 or TLR-9. In this report, we characterized a CD56^＋ DC population that express typical pDC markers including CD123 and BDCA2 but produce much less IFN-I comparing with pDCs. In addition, CD56^＋ DCs cluster together with mDCs but not pDCs by genome-wide transcriptional profiling. Accordingly, CD56^＋ DCs functionally resemble mDCs by producing IL-12 upon TLR4 stimulation and priming naive T cells without prior activation. These data suggest that the CD56^＋ DCs represent a novel mDC subset mixed with some pDC features. A CD4^＋CD56^＋ hematological malignancy was classified as blastic plasmacytoid dendritic cell neoplasm （BPDCN） due to its expression of characteristic molecules of pDCs.However, we demonstrated that BPDCN is closer to CD56^＋ DCs than pDCs by global gene-expression pro- filing. Thus, we propose that the CD4^＋CD56^＋ neoplasm may be a tumor counterpart of CD56^＋ mDCs but not pDCs.
